Search Result
Results for "
co-agonist
" in MedChemExpress (MCE) Product Catalog:
16
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P10032
-
-
-
- HY-W037417
-
|
Xanthine Oxidase
|
Others
|
DAO-IN-1 is a potent inhibitor of D-amino acid oxidase (DAO) with an IC50 value of 269 nM. DAO is an enzyme responsible for D-serine metabolism, D-serine is a co-agonist of NMDA receptors .
|
-
-
- HY-Y0966S8
-
|
Endogenous Metabolite
iGluR
|
Neurological Disease
|
Glycine-d5 is the deuterium labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
|
-
-
- HY-Y0966S1
-
-
-
- HY-Y0966S
-
|
Endogenous Metabolite
iGluR
|
Neurological Disease
|
Glycine- 15N is the 15N-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors .
|
-
-
- HY-Y0966S3
-
-
-
- HY-Y0966S2
-
|
Endogenous Metabolite
iGluR
|
Neurological Disease
|
Glycine-2- 13C is the 13C-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
|
-
-
- HY-Y0966S4
-
|
Endogenous Metabolite
iGluR
|
Neurological Disease
|
Glycine-1- 13C is the 13C-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
|
-
-
- HY-P3375
-
IBI-362; LY-3305677; OXM-3
|
GCGR
GLP Receptor
|
Metabolic Disease
|
Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) .
|
-
-
- HY-Y0966S10
-
|
Isotope-Labeled Compounds
Endogenous Metabolite
iGluR
|
Cancer
|
Glycine-d3 is the deuterium labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
|
-
-
- HY-Y0966S9
-
-
-
- HY-Y0966S6
-
|
Endogenous Metabolite
iGluR
|
Neurological Disease
|
Glycine- 13C2, 15N is the 13C- and 15N-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
|
-
-
- HY-P3375A
-
IBI-362 TFA; LY-3305677 TFA; OXM-3 TFA
|
GCGR
GLP Receptor
|
Metabolic Disease
|
Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide TFA binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D) .
|
-
-
- HY-P10032A
-
-
-
- HY-Y0966S7
-
-
-
- HY-Y0966S5
-
-
-
- HY-101037
-
N-Methylglycine; Sarcosin
|
Endogenous Metabolite
GlyT
|
Cancer
|
Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .
|
-
-
- HY-Y0966S11
-
|
iGluR
Endogenous Metabolite
|
Neurological Disease
|
Glycine- 13C2, 15N,d2 is the deuterium, 13C and 15N labeled Glycine . Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors .
|
-
-
- HY-Y0966
-
Glycine
Maximum Cited Publications
8 Publications Verification
|
Endogenous Metabolite
iGluR
VEGFR
|
Neurological Disease
|
Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is orally active. Glycine can be used to study cell protection, cancer, neurological diseases, and angiogenesis .
|
-
-
- HY-100808
-
(R)-Serine
|
iGluR
Endogenous Metabolite
|
Neurological Disease
|
D-Serine ((R)-Serine), an endogenous amino acid involved in glia-synapse interactions that has unique neurotransmitter characteristics, is a potent co-agonist at the NMDA glutamate receptor. D-Serinee has a cardinal modulatory role in major NMDAR-dependent processes including NMDAR-mediated neurotransmission, neurotoxicity, synaptic plasticity, and cell migration .
|
-
-
- HY-101037S1
-
N-Methylglycine-d3; Sarcosin-d3
|
Isotope-Labeled Compounds
Endogenous Metabolite
GlyT
|
Cancer
|
Sarcosine-d3 is the deuterium labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .
|
-
-
- HY-101037S
-
N-Methylglycine-15N; Sarcosin-15N
|
Endogenous Metabolite
GlyT
|
Cancer
|
Sarcosine- 15N is the 15N-labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .
|
-
-
- HY-101037R
-
N-Methylglycine (Standard); Sarcosin (Standard)
|
Reference Standards
Endogenous Metabolite
GlyT
|
Cancer
|
Sarcosine (Standard) is the analytical standard of Sarcosine. This product is intended for research and analytical applications. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .
|
-
-
- HY-Y0966R
-
|
Reference Standards
Endogenous Metabolite
iGluR
VEGFR
|
Neurological Disease
|
Glycine (Standard) is the analytical standard of Glycine. This product is intended for research and analytical applications. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is orally active. Glycine can be used to study cell protection, cancer, neurological diseases, and angiogenesis .
|
-
-
- HY-100808R
-
(R)-Serine (Standard)
|
Reference Standards
iGluR
Endogenous Metabolite
|
Neurological Disease
|
D-Serine (Standard) is the analytical standard of D-Serine. This product is intended for research and analytical applications. D-Serine ((R)-Serine), an endogenous amino acid involved in glia-synapse interactions that has unique neurotransmitter characteristics, is a potent co-agonist at the NMDA glutamate receptor. D-Serinee has a cardinal modulatory role in major NMDAR-dependent processes including NMDAR-mediated neurotransmission, neurotoxicity, synaptic plasticity, and cell migration[1][2].
|
-
-
- HY-W748519
-
N-Methylglycine-13C3; Sarcosin-13C3
|
Isotope-Labeled Compounds
GlyT
Endogenous Metabolite
|
Cancer
|
Sarcosine- 13C3 (N-Methylglycine- 13C3; Sarcosin- 13C3) is the 13C-labeled Sarcosine (HY-101037). Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .
|
-
-
- HY-100808S
-
(R)-Serine-d3
|
Isotope-Labeled Compounds
Endogenous Metabolite
iGluR
|
Neurological Disease
|
D-Serine-d3 ((R)-Serine-d3) is a deuterium labeled D-Serine (HY-100808). D-Serine ((R)-Serine), an endogenous amino acid involved in glia-synapse interactions that has unique neurotransmitter characteristics, is a potent co-agonist at the NMDA glutamate receptor. D-Serinee has a cardinal modulatory role in major NMDAR-dependent processes including NMDAR-mediated neurotransmission, neurotoxicity, synaptic plasticity, and cell migration .
|
-
-
- HY-100811
-
7-CKA
|
iGluR
|
Neurological Disease
|
7-Chlorokynurenic acid (7-CKA) is a potent and selective antagonist of the glycine B coagonist site of the N-methyl-D-aspartate (NMDA) receptor (IC50=0.56 μM). 7-Chlorokynurenic acid is also a potent inhibitor of the reuptake of glutamate into synaptic vesicles with a Ki of 0.59 μM. 7-Chlorokynurenic acid has potent antinociceptive actions after neuraxial delivery .
|
-
-
- HY-100811A
-
7-CKA sodium salt
|
iGluR
|
Neurological Disease
|
7-Chlorokynurenic acid sodium salt (7-CKA sodium salt) is a potent and selective antagonist of the glycine B coagonist site of the N-methyl-D-aspartate (NMDA) receptor (IC50=0.56 μM). 7-Chlorokynurenic acid sodium salt is also a potent inhibitor of the reuptake of glutamate into synaptic vesicles with a Ki of 0.59 μM. 7-Chlorokynurenic acid sodium salt has potent antinociceptive actions after neuraxial delivery .
|
-
-
- HY-100811AR
-
7-CKA sodium salt (Standard)
|
Reference Standards
iGluR
|
Neurological Disease
|
7-Chlorokynurenic acid (sodium salt) (Standard) is the analytical standard of 7-Chlorokynurenic acid (sodium salt). This product is intended for research and analytical applications. 7-Chlorokynurenic acid sodium salt (7-CKA sodium salt) is a potent and selective antagonist of the glycine B coagonist site of the N-methyl-D-aspartate (NMDA) receptor (IC50=0.56 μM). 7-Chlorokynurenic acid sodium salt is also a potent inhibitor of the reuptake of glutamate into synaptic vesicles with a Ki of 0.59 μM. 7-Chlorokynurenic acid sodium salt has potent antinociceptive actions after neuraxial delivery .
|
-
-
- HY-100811R
-
7-CKA (Standard)
|
Reference Standards
iGluR
|
Neurological Disease
|
7-Chlorokynurenic acid (Standard) is the analytical standard of 7-Chlorokynurenic acid. This product is intended for research and analytical applications. 7-Chlorokynurenic acid (7-CKA) is a potent and selective antagonist of the glycine B coagonist site of the N-methyl-D-aspartate (NMDA) receptor (IC50=0.56 μM). 7-Chlorokynurenic acid is also a potent inhibitor of the reuptake of glutamate into synaptic vesicles with a Ki of 0.59 μM. 7-Chlorokynurenic acid has potent antinociceptive actions after neuraxial delivery .
|
-
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P10032
-
-
- HY-P3375
-
IBI-362; LY-3305677; OXM-3
|
GCGR
GLP Receptor
|
Metabolic Disease
|
Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) .
|
-
- HY-P10032A
-
-
- HY-P3375A
-
IBI-362 TFA; LY-3305677 TFA; OXM-3 TFA
|
GCGR
GLP Receptor
|
Metabolic Disease
|
Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide TFA binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D) .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-Y0966S8
-
|
Glycine-d5 is the deuterium labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
|
-
-
- HY-Y0966S1
-
|
Glycine-d2 is the deuterium labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
|
-
-
- HY-Y0966S
-
|
Glycine- 15N is the 15N-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors .
|
-
-
- HY-Y0966S3
-
|
Glycine- 13C2 is the 13C-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
|
-
-
- HY-Y0966S2
-
|
Glycine-2- 13C is the 13C-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
|
-
-
- HY-Y0966S4
-
|
Glycine-1- 13C is the 13C-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
|
-
-
- HY-Y0966S6
-
|
Glycine- 13C2, 15N is the 13C- and 15N-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
|
-
-
- HY-Y0966S7
-
|
Glycine-2- 13C, 15N is the 13C- and 15N-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
|
-
-
- HY-Y0966S10
-
|
Glycine-d3 is the deuterium labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
|
-
-
- HY-Y0966S9
-
|
Glycine- 15N,d2 is the deuterium and 15N-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
|
-
-
- HY-Y0966S5
-
|
Glycine-1- 13C, 15N is the 13C- and 15N-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
|
-
-
- HY-Y0966S11
-
|
Glycine- 13C2, 15N,d2 is the deuterium, 13C and 15N labeled Glycine . Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors .
|
-
-
- HY-101037S1
-
|
Sarcosine-d3 is the deuterium labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .
|
-
-
- HY-101037S
-
|
Sarcosine- 15N is the 15N-labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .
|
-
-
- HY-W748519
-
|
Sarcosine- 13C3 (N-Methylglycine- 13C3; Sarcosin- 13C3) is the 13C-labeled Sarcosine (HY-101037). Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .
|
-
-
- HY-100808S
-
|
D-Serine-d3 ((R)-Serine-d3) is a deuterium labeled D-Serine (HY-100808). D-Serine ((R)-Serine), an endogenous amino acid involved in glia-synapse interactions that has unique neurotransmitter characteristics, is a potent co-agonist at the NMDA glutamate receptor. D-Serinee has a cardinal modulatory role in major NMDAR-dependent processes including NMDAR-mediated neurotransmission, neurotoxicity, synaptic plasticity, and cell migration .
|
-
Cat. No. |
Product Name |
|
Classification |
-
- HY-Y0966
-
|
|
Fillers
|
Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is orally active. Glycine can be used to study cell protection, cancer, neurological diseases, and angiogenesis .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: